Bupropion as a modulator of drug activity
AssigneeAntecip Bioventures II LLC
InventorHarriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Claims30
A method, comprising administering for at least eight consecutive days a combination of dextromethorphan and bupropion to a human being in need of increased dextromethorphan plasma levels, wherein the human being is an extensive metabolizer of dextromethorphan, wherein the combination is administered in a dosage form having properties effective for providing a Cmax of dextromethorphan on the eighth day of about 40 ng/mL to about 75 ng/mL, and wherein on the eighth day the combination is administered the Cmax of dextromethorphan is at least about 15 times the Cmax of dextromethorphan that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
A method for treating a human being with dextromethorphan, comprising administering dextromethorphan and bupropion once or twice daily for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan, wherein dextromethorphan and bupropion are administered in amounts that result in an AUC0-12 of dextromethorphan on the eighth day that dextromethorphan and bupropion are administered that is about 400 ng·hr/mL to about 700 ng·hr/mL, and wherein the AUC0-12 of dextromethorphan on the eighth day that dextromethorphan and bupropion are administered is at least about 20 times the AUC0-12 of dextromethorphan that would result from administering the same amount of dextromethorphan without bupropion.
Dependencies are inferred from the claim text.